Bayer Withdraws Trasylol From U.S. Market
Posted on: Thursday, 15 May 2008, 12:00 CDT
The U.S. Food and Drug Administration announced the Bayer Pharmaceuticals Corp. is removing its entire stock of the drug Trasylol from the U.S. market.
Last November Bayer agreed to an FDA-requested marketing suspension of Trasylol, a drug used to control bleeding during heart surgery. At that time, preliminary results from a Canadian study suggested the drug produced an increased risk of death compared with two similar drugs.
Now Bayer HealthCare Pharmaceuticals Inc. has notified the FDA it will remove all remaining Trasylol stock, most of which it said is in warehouses and hospitals' or physicians' stock, from the U.S. market.
Although the FDA said, while it hasn't received full study data from the Canadian researchers at the Ottawa Health Research Institute, it supports Bayer's decision.
Source: United Press International
Related Articles
- XDx's AlloMap(R) Gene Expression Test Cleared By U.S. Food and Drug Administration (FDA)
- Commenting on the U.S. Food and Drug Administration (FDA) Early Communication, Allergan Clarifies FDA's Inquiry Relates Primarily to High Dose Medical Uses of BOTOX(R), Rather Than BOTOX(R) Cosmetic for Aesthetic Use
- TyRx Pharma, Inc. Announces Food and Drug Administration (FDA) 510(K) Clearance of the AIGIS(Rx)(TM) Cardiac Rhythm Medical Device (CRMD) Anti-Bacterial Envelope, an Innovative Mesh Envelope Designed to Immobilize and Reduce Bacterial Infection of a Pacem
- Bayer Discontinues Trasylol Study
- TYZEKA(TM) (Telbivudine) Approved By U.S. Food and Drug Administration (FDA) As a New Treatment for Patients With Chronic Hepatitis B
- Chemical Heritage Foundation (CHF) and the Food and Drug Administration (FDA) Will Cosponsor FDA Centennial Conference at CHF on Tuesday, 16 May 2006
- Bayer drug doubles kidney failure risk: study
- U.S. Food and Drug Administration (FDA) Approves BARACLUDE(TM) (Entecavir) for Treatment of Chronic Hepatitis B
- Pulling of MS Drug Calls FDA Actions into Question
User Comments (0)
RSS Feeds